LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
"Chordate". The Encyclopedia of Life. Chordate on GlobalTwitcher.com Chordate node at Tree Of Life Archived 24 February 2007 at the Wayback Machine Chordate node at NCBI Taxonomy Archived 28 April 2021 at the Wayback Machine
== National poll results == Most opinion polls do not cover Northern Ireland, which has different major political parties from the rest of the United Kingdom. In the 'area' column of the tables below, "GB" (Great Britain) denotes polls that do not include Northern Ireland, whereas "UK" (United Kingdom) denotes polls that do. Plaid Cymru only stands candidates in Wales, the Scottish National Party only stands candidates in Scotland, and the Conservative Party is the only party with its own column below that stands candidates in Northern Ireland. Due to rounding, total figures may not add up to 100%. The lead is calculated by subtracting the polling percentage of the first-placed party by that of the second-placed party. The first-placed party is shaded with its party colour, and in boldface; the second-placed party is shaded in grey. The table can be sorted by all features; to sort by party vote share, click on the coloured ribbons. Where polls specify parties within 'other', this may be expandable by pressing the [show] button in the 'other' cell.
Activation of presynaptic dopamine autoreceptors by dihydroergocriptine leads to reduced dopamine receptor turnover and indirect antioxidant effects. In particular, further activation of intracellular kinase systems due to dopamine agonists are hypothesized to lead to antiapoptotic effects that also help in halting and slowing the disease progression. This may also contribute to prevention of development of motor fluctuations, though more research is needed. Modern agonists like dihydroergocryptine typically cost two to three times more than levodopa therapy. More health economics assessments may be needed to determine whether the initial increased costs of the agonists are offset by less patients needing surgery in later stages of the disease.
==== Signs of a good, deep latch ==== In a good latch, a large amount of the areola, in addition to the nipple, is in the baby's mouth. The amount of areola visible on either side of the infant's mouth should be asymmetric, meaning most of the "bottom" of the areola should be in the infant's mouth, and much more of the "top" of the areola should be visible. This position helps point the nipple toward the roof of the infant's mouth, helping the infant recruit more milk. The baby's lips should be flanged out. The neck should be extended to facilitate swallowing, and as such, the chin will be close to the breast, and the forehead and nose should be far from the breast. Another sign of a good latch is the contour of the infant's cheeks; the cheeks should be rounded all the way to the edge of the mouth, rather than dimpled or creased at the edge of the mouth. This is a good indicator of effective suck mechanics. Additionally, to achieve a deep latch, the infant's mouth must be open wide, preferably wider than 140 degrees.
Nancy's bottom-half finish proved a false dawn as the club finished 18th in the 1985–86 season, which meant they had to win a play-off match to avoid relegation. They retained their league status with a 3–2 aggregate win against Mulhouse. The club however sold several of their best players to avoid financial predicament and provided Wenger with little funds to work with. In Wenger's final season in charge, Nancy finished 19th and were relegated to Ligue 2. Despite the setbacks, he was contacted by Monaco over their vacant managerial job. Talks had begun during the summer of 1986, but Nancy chairman Gérard Rousselot refused to release Wenger from his contract, and Monaco were not prepared to offer compensation. Once Nancy's relegation was confirmed, Wenger was permitted to leave the club by mutual consent and was confirmed as Monaco manager in 1987. Before joining Monaco, Wenger had identified several players to build his desired team. Tottenham Hotspur midfielder Glenn Hoddle, granted a free transfer, and Patrick Battiston, out of contract at Bordeaux, were signed. Striker Mark Hateley left Milan to join Monaco and was "encouraged to learn" that his fellow Englishman Hoddle would play in the same side as him. Monaco won the league in Wenger's debut season, six points ahead of runners-up Bordeaux. Although the team scored more goals in 1988–89 due to the purchase of Liberian striker George Weah, Monaco failed to retain the league and finished third behind Marseille and Paris Saint-Germain.
Sources: en.wikipedia.org
India, in July and November 2013, demanded that the U.S. respond to allegations that the Indian UN mission in New York City and the Indian Embassy in Washington, D.C. had been targeted for spying. On July 2, 2014, U.S. diplomats were summoned by the Indian Ministry of External Affairs to discuss allegations that the National Security Agency had spied upon private individuals and political entities within India. A 2010 document leaked by Edward Snowden and published by The Washington Post revealed that US intelligence agencies had been authorized to spy on the Indian Prime Minister Narendra Modi (who was then the chief minister of Gujarat). WikiLeaks revelations that Western intelligence agencies have used foreign aid workers and staff at non-governmental organizations as non-official cover prompted India to step-up the monitoring of satellite phones and movement of personnel working for humanitarian relief organisations and development aid agencies in the vicinity of sensitive locations.
== Other == Apical foramen, the hole at the tip of the root of a tooth Foramen ovale (heart), a hole between the venous and arterial sides of the fetal heart Transverse foramen, one of a pair of openings in each cervical vertebra, in which the vertebral artery travels Greater sciatic foramen, a major foramen of the pelvis Interventricular foramina, channels connecting ventricles in the brain Lesser sciatic foramen, an opening between the pelvis and the posterior thigh Obturator foramen, the hole created by the ischium and pubis bones of the pelvis Omental foramen, the connecting opening between the greater sac and the lesser sac in the abdominal cavity Sacral foramina, which perforate the vertebral canal from the Sacrum (sacral bone), and through which the sacral nerves pass Vertebral foramen, the foramen formed by the anterior segment (the body), and the posterior part, the vertebral arch Foramen of Panizza, a hole connecting two aortas just after they leave the heart in crocodiles
Heated tobacco products were first introduced in 1988, but were not a commercial success. BLOW started selling e-hookahs, an electronic version of the hookah in 2014. The handle of each hose for the e-hookah contains a heating element and a liquid, which produces vapor. Gopal Bhatnagar, based in Toronto, Canada, invented a 3D printed adapter to turn a traditional hookah into an e-hookah. It is used instead of the ceramic bowl that contains shisha tobacco. Rather than the tobacco, users can insert e-cigarettes. Other non‑nicotine aerosol‑generating devices use technology similar to that of electronic cigarettes. Fog machines and haze machines, commonly used in entertainment venues, heat glycol‑based liquids to produce aerosols for visual effects. Industry standards organizations note that the droplets produced by theatrical fog and haze fall within the size range of particulate matter (PM2.5), a classification based on particle diameter. Recent research has shown that heating glycol‑based fluids in both fog and haze machines and electronic cigarettes can produce similar thermal degradation byproducts, including carbonyl compounds such as formaldehyde.
Major issues, however, were not agreed upon in the framework agreement, which contains no accord on Iran's nuclear program or uranium stockpiles, although it does call for the downgrading of Iranian uranium from weapons-grade to reactor-grade following a final agreement. These issues are deferred to future talks to take place over the 60-day ceasefire extension. The framework agreement also does not mention the Iranian ballistic missile program or its network of non-state allies in the Middle East. Within 25 days of signing the memorandum, Iran’s Ministry of Foreign Affairs accused Washington of violating "nearly all parts" of the agreement citing attacks on transport infrastructure and fishing vessels.
==== Government budgetary limitations ==== Instituting MS/MS screening often requires a sizable up front expenditure. When states choose to run their own programs the initial costs for equipment, training and new staff can be significant. Moreover, MS/MS gives only the screening result and not the confirmatory result. The same has to be further done by higher technologies or procedure like GC/MS, Enzyme Assays or DNA Tests. This in effect adds more cost burden and makes physicians lose precious time. To avoid at least a portion of the up front costs, some states such as Mississippi have chosen to contract with private labs for expanded screening. Others have chosen to form Regional Partnerships sharing both costs and resources. But for many states, screening has become an integrated part of the department of health which can not or will not be easily replaced. Thus the initial expenditures can be difficult for states with tight budgets to justify. Screening fees have also increased in recent years as health care costs rise and as more states add MS/MS screening to their programs. (See Report of Summation of Fees Charged for Newborn Screening, 2001–2005) Dollars spent for these programs may reduce resources available to other potentially lifesaving programs. It was recommended in 2006 that one disorder, Short Chain Acyl-coenzyme A Dehydrogenase Deficiency, or SCAD, be eliminated from screening programs, due to a "spurious association between SCAD and symptoms.
Sources: en.wikipedia.org
Bill Gates said that criticizing pharmaceutical company pricing deterred them from investing in medicines for the developing world, and said that instead, pharmaceutical companies should be praised for price discrimination which reduces the price in poor countries. He also advocated improving low-temperature supply chains (a.k.a. cold chains) in developing countries. In August 2019, MSF asked Gavi to stop giving Advance Market Commitment subsidies to GSK and Pfizer, whom they called a duopoly, and instead buy vaccine from a new third manufacturer, the Serum Institute of India, which offered the vaccine at 2/3 of the price then offered by the two. As the pneumococcal vaccine made up 40% of Gavi's vaccine purchasing costs, a 33% price drop would save Gavi billions (13% of its total vaccine purchasing costs). Pneumonia kills more than a quarter of children dying before the age of five, almost a million children each year. MSF said that GSK and Pfizer's pricing was exploitative and had left millions of children who could have been protected vulnerable. Gavi responded that low prices required large, stable, high-volume deals, and "careful consideration and the support of key constituencies". In June 2020, under Gavi's Advance Market Commitment, UNICEF and the Serum Institute of India entered an agreement which reduced the price of pneumococcal conjugate vaccines to $2 per dose.
Aggregate widths can be determined by CP/MAS NMR developed by Innventia AB, Sweden, which also has been demonstrated to work for nanocellulose (enzymatic pre-treatment). An average width of 17 nm has been measured with the NMR-method, which corresponds well with SEM and TEM. Using TEM, values of 15 nm have been reported for nanocellulose from carboxymethylated pulp. However, thinner fibrils can also be detected. Wågberg et al. reported fibril widths of 5–15 nm for a nanocellulose with a charge density of about 0.5 meq./g. The group of Isogai reported fibril widths of 3–5 nm for TEMPO-oxidized cellulose having a charge density of 1.5 meq./g. Pulp chemistry has a significant influence on nanocellulose microstructure. Carboxymethylation increases the numbers of charged groups on the fibril surfaces, making the fibrils easier to liberate and results in smaller and more uniform fibril widths (5–15 nm) compared to enzymatically pre-treated nanocellulose, where the fibril widths were 10–30 nm.
=== Disannexation === In the northern Leribe District, rebel chief Joel Molapo and loyalist chief Jonathan Molapo continued to clash sporadically over the Leribe chieftaincy. Joel continuously attacked local loyalists in an effort to seize power, complicating the settlement of the Gun War. The fighting resulted in a wave of refugees fleeing towards the Orange Free State. A month later, a number of Basuto chiefs including Masopha, failed to appear at a pitso called by Orpen's successor Matt Blyth, thus rejecting Scanlen's new proposal for semi-autonomous rule. Aided by Masopha, Joel Molapo continued to massacre and destroy the properties of his opponents. During one of his raids, his warriors burnt the stone house of his deceased father, which shifted popular opinion against him. In May, Letsie I officially granted Jonathan the Leribe chieftaincy, but despite Letsie's declaration, violence in Leribe did not subside until the end of the year. Facing continued diplomatic protests from the Free State and unable to enforce the law in Basutoland, the Cape Parliament passed the Disannexation Act in September 1883. A pitso held at Maseru on 29 November resulted in most chiefs voting in favor of remaining British subjects. Masopha did not attend the Maseru pitso, holding one of his own; where he demanded complete independence. The British Secretary of State issued an Order-in-Council granting the queen's support to the Disannexation Act, which came into force on 18 March 1884.
==== Post-traumatic growth ==== Posttraumatic growth (PTG) is a possible outcome after a traumatic event, besides posttraumatic stress disorder (PTSD). Following a traumatic event, for instance rape, incest, cancer, attack, or combat, "it is normal to experience debilitating symptoms of depression and anxiety." A person who shows PTG however, will experience these negative outcomes for a time and then show an increase in well-being, higher than it was before the trauma occurred. Martin Seligman, a founder of positive psychology, emphasizes that "arriving at a higher level of psychological functioning than before" is a key point in PTG. If instead an individual experiences a depressive period but recovers from an incident and returns to their normal level of psychological functioning, they are demonstrating resilience. This suggests that in PTG, the trauma acts as a turning point for the person to achieve greater well-being. Seligman recognizes "the fact that trauma often sets the stage for growth" and given the right tools, individuals can make the most of that opportunity." When reflecting on a traumatic growth, Seligman suggests using the following five elements to facilitate PTG: understand the response to trauma, reduce anxiety, utilize constructive disclosure, create a trauma narrative, and articulate life principles and stances that are more robust to challenge.
=== Phylogeny === Viola is one of about 25 genera and about 600 species in the large eudicot family Violaceae, divided into subfamilies and tribes. While most genera are monotypic, Viola is a very large genus, variously circumscribed as having between 500 and 600 species. Historically it was placed in subfamily Violoideae, tribe Violeae. But these divisions have been shown to be artificial and not monophyletic. Molecular phylogenetic studies show that Viola occurs in Clade I of the family, as Viola, Schweiggeria, Noisettia and Allexis, in which Schweiggeria and Noisettia are monotypic and form a sister group to Viola.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.